BR112022017557A2 - Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal - Google Patents

Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal

Info

Publication number
BR112022017557A2
BR112022017557A2 BR112022017557A BR112022017557A BR112022017557A2 BR 112022017557 A2 BR112022017557 A2 BR 112022017557A2 BR 112022017557 A BR112022017557 A BR 112022017557A BR 112022017557 A BR112022017557 A BR 112022017557A BR 112022017557 A2 BR112022017557 A2 BR 112022017557A2
Authority
BR
Brazil
Prior art keywords
stem cells
inflammatory lung
lung diseases
treat inflammatory
line precursor
Prior art date
Application number
BR112022017557A
Other languages
English (en)
Portuguese (pt)
Inventor
Itescu Silviu
Original Assignee
Mesoblast Int Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020900685A external-priority patent/AU2020900685A0/en
Application filed by Mesoblast Int Sarl filed Critical Mesoblast Int Sarl
Publication of BR112022017557A2 publication Critical patent/BR112022017557A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112022017557A 2020-03-05 2021-03-04 Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal BR112022017557A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020900685A AU2020900685A0 (en) 2020-03-05 Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
PCT/EP2021/055483 WO2021176001A1 (en) 2020-03-05 2021-03-04 Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells

Publications (1)

Publication Number Publication Date
BR112022017557A2 true BR112022017557A2 (pt) 2022-12-27

Family

ID=74867509

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017557A BR112022017557A2 (pt) 2020-03-05 2021-03-04 Método para tratar doenças pulmonares inflamatórias com o uso de células-tronco ou precursoras de linhagem mesenquimal

Country Status (9)

Country Link
US (1) US12697355B2 (cg-RX-API-DMAC7.html)
EP (1) EP4114418B1 (cg-RX-API-DMAC7.html)
JP (1) JP2023517035A (cg-RX-API-DMAC7.html)
KR (1) KR20220150919A (cg-RX-API-DMAC7.html)
CN (1) CN115361958A (cg-RX-API-DMAC7.html)
AU (1) AU2021232614A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022017557A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170255A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021176001A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
EP4181935A1 (en) * 2020-07-20 2023-05-24 Brainstorm Cell Therapeutics Ltd. Methods and compositions for treating lung conditions

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5736396A (en) 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US6974571B2 (en) 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US5827740A (en) 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US20030103951A1 (en) 1997-07-14 2003-06-05 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
WO1999003973A1 (en) 1997-07-14 1999-01-28 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
DE69922933T2 (de) 1998-03-13 2005-12-29 Osiris Therapeutics, Inc. Anwendungen für humane nicht autologe, mesenchymale stammzellen
WO1999047163A2 (en) 1998-03-18 1999-09-23 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US20030118567A1 (en) 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
WO1999051247A1 (en) 1998-04-03 1999-10-14 Osiris Therapeutics, Inc. Use of human mesenchymal stem cells to induce t-cell apoptosis
JP2002510655A (ja) 1998-04-03 2002-04-09 オシリス セラピューティクス,インコーポレイテッド 免疫抑制剤としての間葉幹細胞によるt細胞応答を阻害する方法とその利用
US6030836A (en) 1998-06-08 2000-02-29 Osiris Therapeutics, Inc. Vitro maintenance of hematopoietic stem cells
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
AU7611500A (en) 1999-09-24 2001-04-24 Abt Holding Company Pluripotent embryonic-like stem cells, compositions, methods and uses thereof
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
US6936281B2 (en) 2001-03-21 2005-08-30 University Of South Florida Human mesenchymal progenitor cell
US20030104997A1 (en) 2001-09-05 2003-06-05 Black Ira B. Multi-lineage directed induction of bone marrow stromal cell differentiation
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US8105580B2 (en) 2001-12-07 2012-01-31 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to promote wound healing
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
EP1551955A4 (en) 2002-07-16 2006-11-29 Yissum Res Dev Co METHOD FOR IMPLANTING MESENCHYMAL STEM CELLS FOR TISSUE PAIRING AND FORMATION
WO2004009767A2 (en) 2002-07-23 2004-01-29 Boston Scientific Limited Cell therapy for regeneration
US20060210544A1 (en) 2003-06-27 2006-09-21 Renomedix Institute, Inc. Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
CA2564679C (en) 2004-03-22 2015-06-23 Osiris Therapeutics, Inc. Mesenchymal stem cells and uses therefor
ES2385450T3 (es) 2004-03-22 2012-07-25 Osiris Therapeutics, Inc. Células madre mesenquimatosas y sus utilizaciones
JP5162756B2 (ja) 2005-04-14 2013-03-13 財団法人ヒューマンサイエンス振興財団 医薬組成物及びその製造方法
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
US20070253931A1 (en) 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
CN101370930A (zh) 2006-01-13 2009-02-18 奥西里斯治疗公司 表达TNF-α受体的间充质干细胞
EP2057195A4 (en) 2006-08-29 2010-05-12 Forhumantech Co Ltd PHARMACEUTICAL COMPOSITION FOR THE SUPPRESSION OF APOPTOSIS AND METHOD OF ADMINISTERING THE SAME
US20120269774A1 (en) 2006-09-21 2012-10-25 Medistem Laboratories, Inc Allogeneic stem cell transplants in non-conditioned recipients
EP2578677A1 (en) 2007-08-09 2013-04-10 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
KR101039235B1 (ko) 2007-08-29 2011-06-07 메디포스트(주) 제대혈 유래 간엽줄기세포를 포함하는 인터루킨-8 또는지알오-알파 발현 세포가 관련된 질병의 진단, 예방 또는치료용 조성물
KR101995016B1 (ko) 2007-12-04 2019-06-28 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절
WO2009154840A2 (en) 2008-03-27 2009-12-23 Neostem, Inc. Compositions and methods using stem cells in cutaneous wound healing
MX2011001730A (es) 2008-08-14 2011-03-24 Osiris Therapeutics Inc Composiciones purificadas de celulas madre mesenquimales y metodos para purificar composiciones de celulas madre mesenquimales.
WO2011047345A2 (en) 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells
KR101871472B1 (ko) 2010-07-02 2018-06-27 메소블라스트, 아이엔씨. 이식편대숙주 질환의 치료 방법
CA2809272A1 (en) 2010-08-31 2012-03-08 Cook General Biotechnology Llc Systemic, allogenic stem cell therapies for treatment of diseases in animals
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
EP2714057B1 (en) 2011-06-03 2019-11-06 Mesoblast, Inc. Methods of treating or preventing neurological diseases
US20140134140A1 (en) 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections
US20160199413A1 (en) * 2013-08-01 2016-07-14 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
JP6173157B2 (ja) 2013-10-02 2017-08-02 日本製薬株式会社 Il−17産生抑制組成物
WO2015061839A1 (en) 2013-11-04 2015-05-07 Sturm Marian June Cell culture method
CN114317461A (zh) 2013-11-22 2022-04-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
KR102577698B1 (ko) 2014-04-07 2023-09-12 메조블라스트 인터내셔널 에스에이알엘 개선된 줄기 세포 조성물
WO2015189063A1 (en) 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders
WO2016086020A1 (en) 2014-11-24 2016-06-02 Cytostormrx Llc Encapsulated stem cells for the treatment of inflammatory disease
CN107206027A (zh) 2014-12-23 2017-09-26 迈索布拉斯特国际有限公司 进行性心力衰竭的预防
CN105796598A (zh) 2014-12-29 2016-07-27 西比曼生物科技(上海)有限公司 一种用于治疗慢性阻塞性肺疾病的脂肪间充质祖细胞复合物
US20180037867A1 (en) 2015-03-04 2018-02-08 Mesoblast International Sàrl Cell culture method for mesenchymal stem cells
AU2016258980B2 (en) 2015-05-05 2022-02-17 Mesoblast International Sàrl Potency assay
JP7082372B2 (ja) 2017-02-15 2022-06-08 ロート製薬株式会社 肺線維症治療剤、ptprr発現促進剤及び肺線維症治療用キット
EP3619294A1 (en) 2017-05-04 2020-03-11 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
CL2017002357A1 (es) 2017-09-16 2018-04-20 Cells For Cells S A Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
EP4772245A3 (en) 2019-01-02 2026-08-19 Mesoblast International Sàrl Method for treating lower back pain
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
US20220160776A1 (en) 2019-01-28 2022-05-26 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
CN113853206A (zh) 2019-05-23 2021-12-28 迈索布拉斯特国际有限公司 脑梗塞的功能恢复
EP3994245A1 (en) 2019-07-05 2022-05-11 Case Western Reserve University Priming media and methods for stem cell culture and therapy
KR20220038485A (ko) 2019-08-05 2022-03-28 메조블라스트 인터내셔널 에스에이알엘 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법
KR20220143092A (ko) 2020-02-19 2022-10-24 메조블라스트 인터내셔널 에스에이알엘 만성 이식편 대 숙주 질환의 치료 방법
CN111297899A (zh) * 2020-02-21 2020-06-19 云南雅盛医疗科技有限公司 一种脐带间充质干细胞在制备治疗新型冠状肺炎药物中的应用
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
CN115297875A (zh) 2020-03-11 2022-11-04 迈索布拉斯特国际有限公司 治疗炎症性肠病的方法ii
BR112022017560A2 (pt) 2020-03-11 2022-12-27 Mesoblast Int Sarl Método para tratar doença inflamatória intestinal i
JP2023520233A (ja) 2020-04-03 2023-05-16 メゾブラスト・インターナショナル・エスアーエールエル 間葉系統前駆細胞又は幹細胞を使用する過炎症の治療方法
JP2023524660A (ja) 2020-04-28 2023-06-13 ファクター バイオサイエンス インコーポレイテッド 間葉系幹細胞療法
CA3181611A1 (en) 2020-06-11 2021-12-16 Paul Simmons 3d culture of mesenchymal lineage precursor or stem cells
US20230398154A1 (en) 2020-08-10 2023-12-14 Mesoblast International Sárl A composition comprising mesenchymal precursor or stem cells and their use
CN115996735A (zh) 2020-08-10 2023-04-21 迈索布拉斯特国际有限公司 细胞组合物和治疗方法
WO2022132986A2 (en) 2020-12-15 2022-06-23 Mesoblast International Sarl Method of treating progressive heart failure in subjects with class ii heart failure
CN112522191B (zh) 2020-12-18 2023-05-12 云南中科灵长类生物医学重点实验室 一种间充质干细胞的培养方法
AU2022210364A1 (en) 2021-01-22 2023-08-31 Mesoblast International Sàrl Opioid sparing compositions and methods of using the same
BR112023021840A2 (pt) 2021-04-23 2024-02-06 Mesoblast Int Sarl Método para tratar síndrome da dificuldade respiratória aguda (ards) com o uso de percursor de linhagem mesenquimal ou células-tronco
AU2022394471A1 (en) 2021-11-17 2024-06-20 Mesoblast International Sarl Method of treating progressive heart failure in subjects at high risk of poor outcomes
US20250032552A1 (en) 2021-12-23 2025-01-30 Mesoblast International Sárl Method of treating severe graft versus host disease
CA3257272A1 (en) 2022-05-26 2023-11-30 Mesoblast International Sàrl HIGH FLOW FILTER AND METHOD OF USE
EP4536253A1 (en) 2022-06-08 2025-04-16 Mesoblast International Sàrl Mesenchymal progenitor cells for enhancing partial reprogramming of target cells

Also Published As

Publication number Publication date
AU2021232614A1 (en) 2022-09-29
JP2023517035A (ja) 2023-04-21
EP4114418A1 (en) 2023-01-11
CN115361958A (zh) 2022-11-18
EP4114418B1 (en) 2026-05-20
CA3170255A1 (en) 2021-09-10
US20230293589A1 (en) 2023-09-21
WO2021176001A1 (en) 2021-09-10
US12697355B2 (en) 2026-08-04
KR20220150919A (ko) 2022-11-11

Similar Documents

Publication Publication Date Title
BR112022020042A2 (pt) Método para tratar hiperinflamação com o uso de células-tronco ou precursoras de linhagem mesenquimal
BR112022018022A2 (pt) Método para tratar doença inflamatória intestinal ii
BR112023021840A2 (pt) Método para tratar síndrome da dificuldade respiratória aguda (ards) com o uso de percursor de linhagem mesenquimal ou células-tronco
BR112022017560A2 (pt) Método para tratar doença inflamatória intestinal i
MX2024003145A (es) Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
AR081450A1 (es) Tratamiento de sarcoidosis usando celulas madre de placenta
CO2020010342A2 (es) Composiciones de arni de 17 β -hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas
BR112022016448A2 (pt) Método para tratamento de doença do enxerto contra hospedeiro crônica
BR112017027411A2 (pt) inibidores de nadph oxidase 4
MX339658B (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112022007721A2 (pt) Método para o tratamento da demência
BR112016000658A2 (pt) pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
BR112021020525A2 (pt) Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.
BR112015019197A2 (pt) tratamento de doença de enxerto versus hospedeiro em pacientes transplantados
BR112014016950A8 (pt) métodos de promoção da cicatrização de úlceras diabéticas utilizando beta-hidróxi-beta-metilbutirato com arginina e glutamina
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina
BR112022020392A2 (pt) Método para tratar um indivíduo que tem doença de huntington, inibidor do bromodomínio 9, e, uso de um inibidor do bromodomínio 9
BR112023026559A2 (pt) Formas cristalinas de trofinetida
CL2021001172A1 (es) Uso de tivozanib para tratar sujetos con cáncer refractario.
BR112022014456A2 (pt) Tafoxiparina para o tratamento da pré-eclâmpsia
BR112019007259A2 (pt) recipiente de câmara dupla adequado para uso com um nebulizador e pré-carregado com uma composição nebulizável, kit, composição nebulizável, solução nebulizável aquosa, método para administrar de tiotrópio e formoterol a um paciente com necessidade do mesmo e método para preparar um nebulizador
BR112022022204A2 (pt) Usos e formulações de canabinoides